NCT07326839Not yet recruiting
Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT
Optimization of Blood Uric Acid Control in Obese Gout Patients by Orlistat-Mediated Metabolic Remodeling and Intensive Weight Management: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 8 Jan 2026
Brief summary (registry, in English)
A total of 120 obese gout patients were included in a 24-week double-blind randomized controlled design. The intervention group received orlistat 120 mg tid + UTL + individualized diet-exercise-behavioral reinforcement weight loss program, while the control group received a placebo + UTL + standard recommendations. The primary endpoint was the rate of achieving serum uric acid levels \<360 μmol/L at 24 weeks; secondary endpoints included the proportion of weight loss ≥5%, frequency of gout attacks, and inflammatory indicators such as CRP and IL-1β; the activity of AMPK in PBMCs and the expression of HIF1α and NLRP3 inflammasome-related proteins were also assessed.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 10 Dec 2025
- Primary completion date
- 9 Nov 2027
- Lead sponsor
- XueMei Guo
- Diseases
- Obesity
- NCT number
- NCT07326839
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 10 Dec 2025 to the primary completion date, 9 Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to orlistat or other gout medications.
Other illness
- History of severe allergy or adverse reactions to study drugs.
- Malignancy.
Other
- Severe hepatic or renal dysfunction.
- Pregnant or lactating women.
- Secondary gout.
- Poor compliance or inability to cooperate.
- Participation in other clinical trials within the last 3 months.
Who the study is looking for
- Meeting the 2015 ACR/EULAR classification criteria for gout.
- Age 18-70 years.
- BMI ≥28 kg/m².
- Serum uric acid ≥480 μmol/L.
- Willing and able to comply with the study protocol.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| General Hospital of Northern Theater Command, PLA Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.